TOPPAN Holdings Establishes New Company for Cancer Personalized Medicine in the US
TOPPAN Holdings established "TOPPAN Global Medical Healthcare Inc." in Houston, Texas, in March 2026, to advance personalized cancer medicine and drug discovery support. Leveraging its proprietary 3D cell culture technology "invivoid®", the new company will accelerate R&D and local collaborations at the Texas Medical Center, aiming for the societal implementation of personalized medicine.
📋 Article Processing Timeline
- 📰 Published: March 31, 2026 at 19:16
- 🔍 Collected: April 1, 2026 at 13:39 (18h 22m after Published)
- 🤖 AI Analyzed: April 22, 2026 at 01:01 (491h 21m after Collected)
TOPPAN Holdings Inc. (Headquarters: Bunkyo-ku, Tokyo; Representative Director & CEO: Hideharu Maro; hereinafter "TOPPAN Holdings") established a new company, "TOPPAN Global Medical Healthcare Inc.", in Houston, Texas, USA, in March 2026, to promote personalized cancer medicine and drug discovery support businesses.
With the new company as its base, TOPPAN Holdings aims to accelerate research and development using its independently developed 3D cell culture technology "invivoid®" and achieve the societal implementation of personalized cancer medicine. The new company is located in the Texas Medical Center (TMC), where world-class cancer research facilities are concentrated, and will promote collaboration with local medical institutions and pharmaceutical companies.
■ Background of New Company Establishment
Currently, in the field of cancer treatment, there is a globally increasing need for "personalized medicine" that selects the optimal treatment method and drugs for each patient. In this context, TOPPAN Holdings concluded a strategic alliance with The University of Texas MD Anderson Cancer Center (Texas, USA; hereinafter "UT MD Anderson") in July 2025, and has been jointly developing clinical tools to evaluate treatment efficacy from patient-derived samples.
The newly established company will serve as a core base to directly handle collaborations with local medical institutions and pharmaceutical companies in the US, the world's largest medical market, and will promote the expansion of personalized cancer treatment and drug discovery support businesses.
■ Objectives of New Company Establishment
・Acceleration of Clinical Validation
Deepen joint research with UT MD Anderson Cancer Center, accelerate clinical validation research across multiple cancer types, and aim to acquire certification from the College of American Pathologists (CAP) / Clinical Laboratory Improvement Amendments (CLIA).
・Development of Drug Discovery Support Business
Provide an efficient drug discovery screening environment using "invivoid®" to major US pharmaceutical companies, contributing to the acceleration and sophistication of new drug development.
・Construction of Global Network
Based in Houston, a hub of medical innovation, the company will incorporate cutting-edge knowledge, talent, and research institution networks to promote global business development.
■ Overview of the New Company
Trade Name: TOPPAN Global Medical Healthcare Inc.
Location: (The original text was truncated here, so this part is incomplete.)
With the new company as its base, TOPPAN Holdings aims to accelerate research and development using its independently developed 3D cell culture technology "invivoid®" and achieve the societal implementation of personalized cancer medicine. The new company is located in the Texas Medical Center (TMC), where world-class cancer research facilities are concentrated, and will promote collaboration with local medical institutions and pharmaceutical companies.
■ Background of New Company Establishment
Currently, in the field of cancer treatment, there is a globally increasing need for "personalized medicine" that selects the optimal treatment method and drugs for each patient. In this context, TOPPAN Holdings concluded a strategic alliance with The University of Texas MD Anderson Cancer Center (Texas, USA; hereinafter "UT MD Anderson") in July 2025, and has been jointly developing clinical tools to evaluate treatment efficacy from patient-derived samples.
The newly established company will serve as a core base to directly handle collaborations with local medical institutions and pharmaceutical companies in the US, the world's largest medical market, and will promote the expansion of personalized cancer treatment and drug discovery support businesses.
■ Objectives of New Company Establishment
・Acceleration of Clinical Validation
Deepen joint research with UT MD Anderson Cancer Center, accelerate clinical validation research across multiple cancer types, and aim to acquire certification from the College of American Pathologists (CAP) / Clinical Laboratory Improvement Amendments (CLIA).
・Development of Drug Discovery Support Business
Provide an efficient drug discovery screening environment using "invivoid®" to major US pharmaceutical companies, contributing to the acceleration and sophistication of new drug development.
・Construction of Global Network
Based in Houston, a hub of medical innovation, the company will incorporate cutting-edge knowledge, talent, and research institution networks to promote global business development.
■ Overview of the New Company
Trade Name: TOPPAN Global Medical Healthcare Inc.
Location: (The original text was truncated here, so this part is incomplete.)